Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 15

Results For "Biologics"

513 News Found

Shilpa Biologics permitted to conduct Phase 1 study on NavAlbumin
Biotech | November 05, 2021

Shilpa Biologics permitted to conduct Phase 1 study on NavAlbumin

The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent


Biocon Biologics’ interchangeable biosimilar insulin Glargine preferred on Express Scripts
News | October 21, 2021

Biocon Biologics’ interchangeable biosimilar insulin Glargine preferred on Express Scripts

Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)


Thermo Fisher opens biologics site in Lengnau, Switzerland
News | October 04, 2021

Thermo Fisher opens biologics site in Lengnau, Switzerland

The state-of-the-art facility provides a pathway from development to large-scale biologics production


U.S. FDA completes inspection of Biocon Biologics, Malaysia with six observations
Biotech | September 26, 2021

U.S. FDA completes inspection of Biocon Biologics, Malaysia with six observations

The company does not expect the outcome of this inspection to impact its plans


Boehringer Ingelheim acquires Abexxa Biologics to advance its cancer research
Biotech | September 22, 2021

Boehringer Ingelheim acquires Abexxa Biologics to advance its cancer research

The addition of Abexxa’s expertise complements Boehringer Ingelheim’s current approaches to the treatment of difficult-to-treat solid cancers and especially those resistant to available immunotherapies


Biocon Biologics to offer Serum Institute of Life Sciences 15 pc stake at US $ 4.9 billion valuation
Biotech | September 17, 2021

Biocon Biologics to offer Serum Institute of Life Sciences 15 pc stake at US $ 4.9 billion valuation

BB will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets


Biocon Biologics and Viatris receive approval for first interchangeable biosimilar Semglee
Drug Approval | August 12, 2021

Biocon Biologics and Viatris receive approval for first interchangeable biosimilar Semglee

The company is eligible for 12 months exclusivity from launch


Biocon Biologics partners Adagio to manufacture antibody for COVID-19
News | July 27, 2021

Biocon Biologics partners Adagio to manufacture antibody for COVID-19

ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses


Biocon Biologics and Viatris receive European Commission approval for Kixelle, Biosimilar Insulin Aspart
Biotech | February 13, 2021

Biocon Biologics and Viatris receive European Commission approval for Kixelle, Biosimilar Insulin Aspart

The centralized marketing authorization granted by the EC is valid in all EU Member


Biocon Biologics to offer its oncology biosimilars in 30+ countries
Biotech | February 05, 2021

Biocon Biologics to offer its oncology biosimilars in 30+ countries

The partnership is a significant step in delivering advanced cancer therapies to patients.